LOTTE Biologics has signed a commercial manufacturing agreement with a global pharmaceutical company to supply products from Plant 1 at its Songdo Bio Campus. Under the agreement, LOTTE will provide integrated drug substance and drug product manufacturing services for products in the customer's portfolio, with commercial production targeted to begin in 2027.
The agreement represents the first major commercial manufacturing commitment for Songdo Plant 1 and was secured ahead of the facility's operational launch. The company said securing manufacturing volume while the facility remains under development aligns its capacity expansion with customer commitments.
Plant 1 will provide 120,000 liters of manufacturing capacity through eight 15,000-liter stainless-steel bioreactors. The broader Songdo Bio Campus is being developed with planned capacity of 360,000 liters across three plants, with infrastructure that includes automation and large-scale cold-chain warehousing to support manufacturing operations.
Songdo will complement LOTTE's Syracuse Bio Campus in New York, which has more than two decades of manufacturing experience and a record supporting more than 62 regulatory approvals. The Syracuse site also recently completed an FDA inspection with zero observations, according to the company.
LOTTE said the two campuses will form an integrated manufacturing network intended to provide operational flexibility, consistent quality standards and greater supply-chain resilience across its operations. Co-Chief Executive Officer James Park said the company plans to combine Syracuse's manufacturing experience with Songdo's infrastructure as part of its strategy to establish a globally integrated manufacturing platform, with the latest agreement providing a commercial commitment for the new plant before its planned production launch next year.